Bulbine natalensis to Improve Testosterone

Evidence Review created on 05/09/2026 using AI4L / Opus 4.7

Also known as: Rooiwortel, Ibhucu, Broad-leaved Bulbine

Motivation

Bulbine natalensis is a succulent plant native to southern Africa, traditionally used by Zulu and Xhosa healers for wound healing, infections, and as a tonic for vitality. In the supplement market, its stem extracts are sold primarily as a natural testosterone booster, with claims rooted almost entirely in a small body of rodent studies reporting large increases in serum testosterone.

The plant entered bodybuilding and longevity supplement formulations in the early 2010s following rat studies suggesting androgenic effects, and remains a common ingredient in “test booster” products. The same animal studies, alongside subsequent toxicology reports, also raised concerns about hepatic and renal toxicity at higher doses, leaving a disconnect between marketing claims and the underlying evidence.

This review examines what is currently known about Bulbine natalensis stem extract for raising testosterone in adults, the strength and limitations of the supporting evidence, the proposed mechanisms, the safety signals reported in animal models, and how these factors translate into practical considerations for a longevity-oriented audience.

Benefits - Risks - Protocol - Conclusion

Recommended Reading

The following resources offer high-level context on Bulbine natalensis as a putative testosterone-supporting botanical, drawn from the foundational primary research literature.

• Anabolic and androgenic activities of Bulbine natalensis stem in male Wistar rats - Yakubu & Afolayan, 2010

  The foundational primary research paper that reported large increases in serum testosterone, luteinizing hormone, and follicle-stimulating hormone in male rats, on which most subsequent supplement marketing is based.

• Modulation of CYP3A4 and CYP2C9 activity by Bulbine natalensis and its constituents: An assessment of HDI risk of B. natalensis containing supplements - Husain et al., 2021

  An independent University of Mississippi study assessing herb-drug interaction risk. It identifies knipholone constituents as potent inducers of CYP3A4 (a major cytochrome P450 enzyme metabolizing many xenobiotics) and CYP2C9 (a cytochrome P450 enzyme that metabolizes many drugs), giving safety context for users combining Bulbine natalensis with prescription medications.

Note: No dedicated content on Bulbine natalensis was located from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, or Life Extension Magazine as of the creation date; only two primary-research papers from independent sources met the eligibility criteria for this section without violating the one-item-per-source rule (the Hofheins et al. 2012 short-term human safety abstract is the only published human study on Bulbine natalensis and is discussed in the body of the review, but it is a JISSN supplement abstract not indexed in PubMed and is therefore not listed here), so fewer than 5 entries are listed and the list has not been padded with marginally relevant content.

Grokipedia

No dedicated Grokipedia article on Bulbine natalensis was found as of the creation date.

Examine

• Bulbine natalensis - Health benefits, dosage, safety, side effects, and more

  Examine’s dedicated page summarizes the available human and animal evidence on Bulbine natalensis for testosterone, libido, and safety, and is one of the few independent, citation-grounded overviews of the compound.

ConsumerLab

No dedicated ConsumerLab review of Bulbine natalensis products was found as of the creation date.

Systematic Reviews

No systematic reviews or meta-analyses for Bulbine natalensis were found on PubMed as of 05/09/2026.

Mechanism of Action

The proposed mechanism by which Bulbine natalensis stem extract may increase testosterone is not fully established and rests primarily on rodent data.

The most cited hypothesis comes from animal studies suggesting the extract acts on the hypothalamic-pituitary-gonadal (HPG) axis (the hormonal feedback loop between the brain and testes). Increases in luteinizing hormone (LH, the pituitary hormone that signals the testes to produce testosterone) and follicle-stimulating hormone (FSH, which supports sperm production) have been reported in male rats given aqueous extracts of the stem. This profile resembles a centrally acting stimulator of endogenous testosterone production rather than direct androgen receptor activation.

A second proposed mechanism involves direct effects on testicular Leydig cells (the testosterone-producing cells in the testes), with reports of increased testicular cholesterol and steroidogenic enzyme activity in rodent models. Phytochemical analyses point to anthraquinones, saponins, alkaloids, and phenolic compounds as candidate active constituents, though no single molecule has been confirmed as the testosterone-modulating agent.

Competing interpretations exist. Some authors argue the apparent androgenic effects in rats may be confounded by stress modulation or hepatotoxicity-driven changes in hormone clearance, since the same extract has been shown to alter liver enzyme activity. Whether any of these mechanisms translate to humans at supplement-typical doses is unverified, as no published human pharmacokinetic or endocrine studies have characterized Bulbine natalensis in vivo.

Bulbine natalensis is a botanical mixture rather than a single pharmacological compound, so half-life, selectivity, tissue distribution, and metabolism are not formally characterized. Anthraquinone constituents are typically conjugated and excreted via hepatic and renal pathways; cytochrome P450 (CYP) involvement has been suggested but not mapped.

Historical Context & Evolution

Bulbine natalensis has a long history of use in southern African traditional medicine, particularly among Zulu and Xhosa healers. Stems and roots were used topically for wounds, burns, rashes, and insect bites, and internally as a tonic for vitality, fertility, and infections. It was not historically marketed or used specifically as a testosterone booster — that framing is a modern, post-2009 supplement-industry development.

The shift toward androgenic positioning began with a series of rodent studies published in the late 2000s by Yakubu and colleagues, reporting that aqueous stem extracts increased serum testosterone, LH, FSH, and testicular weight in male Wistar rats. These findings were quickly adopted by the bodybuilding and natural supplement industries, and Bulbine natalensis became a staple ingredient in “test booster” formulations. Conflict of interest note: virtually all positive androgenic findings on Bulbine natalensis derive from a single related research group, and the predominant non-academic advocates for the ingredient are dietary-supplement manufacturers whose revenue depends on continued use of the compound; both should be considered when weighing the literature.

Subsequent investigations from the same and related research groups raised hepatic and renal safety questions, with reports of altered liver and kidney function markers and histological changes at higher doses. These findings have not consistently been transmitted to consumer-facing materials, creating an asymmetry between the popularity of the ingredient and the cautionary signals in the underlying literature.

To date, no large, well-controlled human randomized trials on Bulbine natalensis for testosterone have been published. The current standing of the intervention is therefore best described as: a traditional African botanical with promising rodent data on testosterone, paired with concerning rodent data on liver and kidney function, and minimal direct human evidence either way.

Expected Benefits

A dedicated search of clinical and expert sources was performed to characterize the benefit profile of Bulbine natalensis, drawing on the available rodent literature, examine.com summaries, and traditional-use accounts.

High 🟩 🟩 🟩

No benefits of Bulbine natalensis meet the High evidence threshold (multiple high-quality human randomized controlled trials (RCTs) or meta-analyses) at this time.

Medium 🟩 🟩

No benefits of Bulbine natalensis meet the Medium evidence threshold (well-conducted human studies) at this time.

Low 🟩

Increased Serum Testosterone in Male Rodents

Aqueous and ethanolic extracts of Bulbine natalensis stem have been reported to substantially increase serum testosterone in male Wistar rats, with some studies describing several-fold elevations versus controls. Proposed mechanisms include stimulation of the HPG axis and Leydig cell steroidogenesis. The evidence base is limited to rodent studies, primarily from a small number of related research groups, and has not been replicated in adequately powered human trials.

Magnitude: In rat studies, increases of roughly 1.5- to 3-fold over baseline serum testosterone have been reported at oral doses of 25–100 mg/kg over 1–2 weeks; human-equivalent translation is unverified.

Improved Sexual Behavior Markers in Male Rodents

Rodent studies have reported increases in mounting frequency, intromission frequency, and reduced mount latency in male rats given Bulbine natalensis stem extracts, alongside increases in serum testosterone. The proposed mechanism is androgenic potentiation via increased endogenous testosterone, with possible secondary effects on nitric oxide signaling. Limitations include short study durations, narrow dose ranges, and a lack of validated human libido endpoints for this compound.

Magnitude: Not quantified in available studies.

Speculative 🟨

Support for Male Fertility Markers

A speculative benefit is improved sperm parameters and fertility markers, based on rodent reports of increased testicular weight and altered seminiferous tubule histology with low-dose extracts, alongside hypothesized HPG-axis stimulation. No controlled human studies are available; the basis is mechanistic and animal-derived only.

Pro-Androgenic Body Composition Effects

A speculative benefit is improved body composition (lean mass, fat mass) via raised endogenous testosterone, by analogy to other pro-androgenic interventions. There are no controlled human studies of Bulbine natalensis using body composition endpoints; the basis is mechanistic and inferred from rodent androgenic signals only.

Mood and Motivation Effects via Testosterone

A speculative benefit is improvement in mood, motivation, and well-being secondary to elevated androgens, again by analogy to other interventions that raise endogenous testosterone in hypogonadal men. No controlled human data on Bulbine natalensis and mood endpoints are available; the basis is mechanistic only.

Benefit-Modifying Factors

• Baseline testosterone level: Individuals with lower-normal or sub-clinical low testosterone may have a larger relative response to any pro-androgenic intervention than those starting in the upper-normal range, where homeostatic feedback tends to limit further increases. This pattern is well established for testosterone-modulating interventions in general; whether it applies specifically to Bulbine natalensis is unverified.

• Sex: Available rodent data are exclusively in males. Effects in females, where androgen elevations may produce unwanted virilizing effects rather than benefits, are not characterized and are a likely contraindication for routine use.

• Age: Older men with age-related decline in HPG-axis function may theoretically respond differently than younger men with intact gonadal function; rodent data primarily come from young adult animals, and translation to older human cohorts is unverified.

• Pre-existing liver and kidney function: Because the same rodent literature flags hepatic and renal effects, individuals with impaired liver or kidney function are likely to have both a different pharmacokinetic profile and a less favorable risk-benefit balance, even if some androgenic effect is present.

• Genetic polymorphisms in steroidogenic and hepatic enzymes: Polymorphisms in CYP3A4 (a major cytochrome P450 enzyme metabolizing many xenobiotics), CYP17A1 (an enzyme involved in androgen synthesis), and SHBG (sex hormone-binding globulin, the protein that binds and transports testosterone in blood) regulators may modify both response and safety; specific data on Bulbine natalensis are not available.

Potential Risks & Side Effects

A dedicated search of toxicology literature, primary research, and consumer safety reports was performed to characterize the risk profile of Bulbine natalensis.

High 🟥 🟥 🟥

No risks of Bulbine natalensis are supported by High-quality human evidence (multiple human RCTs or large pharmacovigilance datasets) at this time.

Medium 🟥 🟥

Hepatotoxicity (Elevated Liver Enzymes and Histological Changes)

Multiple rodent studies, including those by the same research group that reported testosterone increases, observed elevated liver enzymes (ALT (alanine aminotransferase, an enzyme released when liver cells are damaged), AST (aspartate aminotransferase, another liver-injury marker also present in muscle), ALP (alkaline phosphatase, a liver and bone enzyme that rises with bile-duct stress)) and histological changes in the liver at moderate-to-high doses of Bulbine natalensis stem extract. Proposed mechanisms include direct hepatocellular toxicity from anthraquinone constituents and oxidative stress. Severity is dose-dependent in rodents. The single published human safety trial (Hofheins et al., 2012; 36 healthy men, 650 mg/day, 28 days) reported no clinically significant hepatic enzyme changes — providing limited reassurance at that specific dose and duration but not generalizable to higher doses, longer use, or susceptible populations.

Magnitude: Not quantified in available studies.

Nephrotoxicity (Altered Kidney Function Markers)

Rodent studies have reported elevations in serum urea, creatinine, and altered kidney histology at moderate-to-high doses of Bulbine natalensis. The proposed mechanism includes direct tubular toxicity and possibly secondary effects of altered hepatic metabolism. Reversibility appears partial in some animal studies. The single published human safety trial (Hofheins et al., 2012; 36 healthy men, 650 mg/day, 28 days) found no clinically significant changes in renal biomarkers — limited reassurance at that exposure but not extrapolable to higher doses, longer exposure, or those with reduced renal reserve.

Magnitude: Not quantified in available studies.

Low 🟥

Suppression of Endogenous Testosterone with Higher Doses ⚠️ Conflicted

Some rodent studies, particularly at higher doses or longer durations, have observed paradoxical decreases in serum testosterone, LH, or FSH, suggesting a biphasic dose-response or HPG-axis suppression at supraphysiological exposures. This is in direct conflict with the lower-dose pro-androgenic findings from the same and related research groups. The evidence base is small, primarily rodent, and the dose-response relationship in humans is unmapped.

Magnitude: Not quantified in available studies.

Gastrointestinal Disturbance

Anthraquinone-containing botanicals are commonly associated with gastrointestinal effects such as cramping, nausea, and laxative effects. Bulbine natalensis stem contains anthraquinones and may produce similar effects, particularly at higher doses or in sensitive individuals. Evidence is largely mechanistic and inferred from related botanicals; case-level human reports are sparse.

Magnitude: Not quantified in available studies.

Speculative 🟨

Estrogen-Related Effects via Aromatization

A speculative risk is estrogen-related effects (such as gynecomastia (development of breast tissue in men) or fluid retention) if Bulbine natalensis meaningfully raises endogenous testosterone, since aromatization to estradiol could follow. There are no human studies measuring estradiol or related endpoints with Bulbine natalensis; the basis is mechanistic only.

Cardiovascular Effects from Sustained Androgen Elevation

A speculative risk is cardiovascular effects (such as hematocrit elevation or blood pressure changes) by analogy to exogenous testosterone therapy, if Bulbine natalensis sustains meaningful endogenous testosterone elevation. No clinical cardiovascular outcome data are available; the basis is mechanistic and analogical only.

Drug-Induced Liver Injury in Susceptible Users

A speculative risk is idiosyncratic drug-induced liver injury (DILI) in genetically or metabolically susceptible individuals using Bulbine natalensis alongside other hepatotoxic agents (alcohol, prescription medications, other herbs). The basis is mechanistic and from isolated case reports of hepatotoxicity associated with botanical “test booster” stacks containing Bulbine natalensis.

Risk-Modifying Factors

• Baseline biomarker levels: Baseline elevations in liver enzymes (ALT or AST above the upper limit of normal), GGT (gamma-glutamyl transferase, an early marker of liver and bile-duct stress), or bilirubin, and a reduced eGFR (estimated glomerular filtration rate, a measure of kidney filtering capacity; e.g., <90 mL/min/1.73 m²) materially increase the risk of clinically significant hepatic or renal injury during use; the lower the baseline reserve, the smaller the on-treatment shift required to cross a stop-line threshold.

• Pre-existing liver disease: Individuals with fatty liver disease, hepatitis, cirrhosis, or recent liver enzyme elevations are at higher risk for hepatotoxicity given the rodent and case-report signals, and likely the most important risk-modifying factor for this intervention.

• Pre-existing kidney disease: Individuals with reduced eGFR, proteinuria, or known nephropathy are at elevated risk for nephrotoxic effects suggested by rodent studies.

• Concomitant hepatotoxic exposure: Heavy alcohol use, regular acetaminophen use, anabolic steroid use, or stacking with other hepatotoxic herbs (e.g., kava, comfrey, certain “test booster” blends) may amplify hepatic risk.

• Sex: Women are likely to experience androgenic side effects (acne, hair-pattern changes, voice changes) rather than benefits, and rodent safety data for females are limited.

• Age: Older adults often have reduced hepatic and renal reserve and are more prone to drug-induced liver and kidney injury overall, increasing the risk profile of any hepatotoxic or nephrotoxic agent.

• Genetic polymorphisms in hepatic metabolism: Polymorphisms in CYP3A4, CYP2C9 (a cytochrome P450 enzyme that metabolizes many drugs and xenobiotics), and UGT1A1 (an enzyme involved in glucuronidation and bilirubin clearance) may alter individual susceptibility to anthraquinone-mediated hepatic effects, though specific data on Bulbine natalensis are unavailable.

Key Interactions & Contraindications

• Hepatotoxic prescription drugs (e.g., methotrexate, isoniazid, amiodarone, valproic acid, statins such as atorvastatin): Caution; combined hepatic stress is plausible. Suggested mitigation is avoidance or close monitoring of liver enzymes (ALT, AST) at baseline and during co-administration.

• Nephrotoxic prescription drugs (e.g., aminoglycosides such as gentamicin, NSAIDs (non-steroidal anti-inflammatory drugs, a class that includes ibuprofen and naproxen) at high dose, certain chemotherapeutics): Caution; additive nephrotoxic risk is plausible based on rodent data. Suggested mitigation is avoidance or monitoring of creatinine and eGFR.

• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) and aromatase inhibitors (e.g., anastrozole, letrozole): Caution; if Bulbine natalensis meaningfully raises endogenous testosterone, downstream conversion to dihydrotestosterone (DHT) and estradiol may be altered, with unpredictable net effects.

• Exogenous testosterone or anabolic-androgenic steroids: Caution to absolute contraindication for combined use; layering pro-androgenic botanicals on exogenous androgens carries risk of supraphysiological exposure, hematocrit elevation, and HPG-axis suppression on cycle and post-cycle.

• OTC anthraquinone-containing laxatives (e.g., senna, cascara) and aloe vera (oral): Caution; combined anthraquinone load may amplify gastrointestinal and potentially hepatic effects.

• OTC analgesics (acetaminophen at chronic high dose, NSAIDs): Caution; chronic acetaminophen plus Bulbine natalensis may increase hepatotoxic risk; chronic NSAID use plus Bulbine natalensis may increase nephrotoxic risk.

• Other herbal “test boosters” (e.g., Tribulus terrestris, Eurycoma longifolia (tongkat ali), fenugreek, ashwagandha): Caution; stacking provides minimal incremental evidence-based benefit while compounding hepatic and unknown-interaction risk.

• Hepatotoxic herbs and supplements (e.g., kava, comfrey, chaparral, high-dose green tea extract): Caution to avoidance; combined use raises hepatic risk substantially.

• Supplements with additive androgenic or HPG-axis effects (e.g., DHEA (dehydroepiandrosterone, an adrenal androgen precursor), pregnenolone, high-dose zinc): Caution; potential for supraphysiological androgen exposure and unpredictable feedback.

• Anticoagulants and antiplatelets (e.g., warfarin, apixaban, clopidogrel): Caution; some anthraquinone-containing herbs alter hepatic metabolism of CYP-cleared anticoagulants. Monitor INR (international normalized ratio, a standardized measure of how long blood takes to clot) or coagulation status if used together.

• Populations who should avoid this intervention:

  • Individuals with known liver disease (e.g., chronic hepatitis B/C, NAFLD (non-alcoholic fatty liver disease, fat buildup in the liver unrelated to alcohol) with elevated ALT/AST, Child-Pugh Class A or worse)
  • Individuals with chronic kidney disease (eGFR <60 mL/min/1.73 m²)
  • Individuals with hormone-sensitive cancers (e.g., prostate cancer, hormone-responsive breast cancer)
  • Individuals with untreated benign prostatic hyperplasia with significant lower urinary tract symptoms
  • Individuals using exogenous testosterone or anabolic-androgenic steroids
  • Pregnant or breastfeeding women
  • Individuals under 18 years of age
  • Individuals on multiple known hepatotoxic medications

Risk Mitigation Strategies

• Conservative starting dose: Begin at the lower end of marketed dosing (e.g., 100–200 mg of standardized stem extract daily) for at least 1–2 weeks before any escalation, to identify early intolerance and reduce the chance of dose-dependent hepatic or gastrointestinal effects.

• Baseline liver and kidney panel: Obtain baseline ALT, AST, ALP, GGT, total bilirubin, BUN (blood urea nitrogen, a kidney function marker reflecting nitrogen waste in the blood), creatinine, and eGFR before starting, to provide a reference point for detecting hepatic or renal injury during use; this directly mitigates the hepatotoxicity and nephrotoxicity risks.

• On-treatment monitoring: Repeat liver and kidney panels at 4–6 weeks of use and again at 12 weeks, with discontinuation if ALT or AST rises more than 2–3 times the upper limit of normal, or eGFR drops more than 10–15% from baseline; this directly mitigates progression of hepatic and renal injury before symptoms appear.

• Time-limited use cycles: Limit continuous use to discrete cycles (e.g., 8–12 weeks on, 4–8 weeks off) rather than indefinite daily intake, to reduce cumulative exposure to anthraquinone and other phytochemical constituents implicated in hepatic and renal effects.

• Avoidance of stacking with other hepatotoxic agents: Avoid concurrent use with alcohol (limit to ≤1 drink/day), acetaminophen at chronic doses >2 g/day, and any other herbal product flagged for hepatic risk, to limit additive hepatotoxic load.

• No combination with exogenous androgens: Avoid simultaneous use with testosterone replacement therapy or anabolic-androgenic steroids; this prevents supraphysiological androgen exposure and helps mitigate the speculative cardiovascular and prostate-related risks.

• Hormonal monitoring at higher doses or longer cycles: For individuals using Bulbine natalensis longer than 8 weeks, consider testing total testosterone, free testosterone, estradiol, and SHBG to detect the dose-related biphasic suppression risk and any meaningful hormonal change.

• Discontinuation on adverse signal: Discontinue immediately on symptoms suggestive of hepatic injury (jaundice, dark urine, persistent right upper quadrant pain, severe fatigue, nausea/vomiting) or renal injury (sudden change in urine output, unexplained edema), to mitigate progression to clinically significant injury.

Therapeutic Protocol

• Standard marketed protocol: Manufacturers and informal practitioner reports typically describe oral Bulbine natalensis stem extract at 100–650 mg/day, often standardized to a 10:1 or 20:1 extract ratio, for 8–12 week cycles. This is not derived from controlled human dose-finding studies; it is extrapolated from rodent dose ranges and accumulated user experience.

• Conservative integrative approach: Integrative-medicine and functional-medicine practitioners (e.g., the Chris Kresser Institute for Functional Medicine; clinicians influenced by Examine.com’s risk-aware framing of pro-androgenic herbs) typically use Bulbine natalensis at the low end of marketed dosing (100–250 mg/day), often combined with broader testosterone-supportive lifestyle and nutritional measures (zinc adequacy, sleep optimization, resistance training), positioning it as one component of a multi-pronged approach rather than a standalone treatment.

• Conventional medical approach: Conventional endocrinology does not generally use or recommend Bulbine natalensis. For confirmed clinical hypogonadism, the standard approach is investigation of underlying causes followed by testosterone replacement therapy where indicated, not botanical supplementation.

• Best time of day: No human pharmacokinetic studies define optimal timing. Many users take it in the morning to align with the diurnal testosterone peak, often with food to reduce gastrointestinal effects. An alternative is split dosing with breakfast and lunch to maintain more even exposure.

• Half-life considerations: No formal pharmacokinetic data on Bulbine natalensis in humans are available. Anthraquinone constituents are typically cleared within hours to a day; this argues for daily dosing rather than every-other-day or weekly schedules if any pharmacological effect is to be sustained.

• Single vs. split dosing: Given the absence of pharmacokinetic data, both single morning dosing and split (twice-daily) dosing are used in practice. Split dosing is often preferred at higher total daily doses (>300 mg) to limit peak exposure.

• Genetic polymorphisms: No pharmacogenetic studies of Bulbine natalensis exist. Theoretical considerations include CYP3A4 and CYP2C9 variant carriers (who may metabolize phytochemicals differently) and individuals with UGT1A1 polymorphisms (e.g., Gilbert’s syndrome, a common benign condition causing mildly elevated bilirubin from reduced UGT1A1 activity) who may have altered anthraquinone handling.

• Sex-based differences: All available rodent efficacy data are in males. Use in women is generally not recommended; if attempted at all, the rationale, dosing, and monitoring would have to be individualized given the lack of female-specific data.

• Age-related considerations: Older adults (60+) have reduced hepatic and renal reserve and a higher prevalence of polypharmacy, so a lower dose, more conservative cycling, and more frequent monitoring are appropriate.

• Baseline biomarker considerations: Baseline total testosterone, free testosterone, SHBG, LH, and estradiol help identify candidates with measurable low-normal androgen status and provide a reference point for assessing response.

• Pre-existing health conditions: Individuals with hepatic impairment, renal impairment, hormone-sensitive cancer, or significant prostate disease should generally not use this intervention; protocol decisions in these populations require physician oversight.

Discontinuation & Cycling

• Lifelong vs. short-term use: Bulbine natalensis is not designed or characterized for lifelong daily use. Available rodent data and the hepatic/renal signals argue for time-limited use, typically in the context of discrete cycles rather than indefinite intake.

• Withdrawal effects: No formally characterized withdrawal syndrome has been reported. If endogenous testosterone has been transiently elevated, a return toward baseline is expected on cessation; in users who have stacked it with other pro-androgenic interventions, the perceived “drop-off” may be amplified.

• Tapering protocol: Formal tapering is not established. Given the short expected half-life of constituents, abrupt cessation is generally well tolerated, though some practitioners prefer a brief step-down (e.g., halving the dose for 1–2 weeks) when ending longer cycles.

• Cycling for efficacy: Cycling is commonly recommended in the supplement literature both to mitigate cumulative hepatic and renal exposure and to reduce theoretical receptor desensitization or HPG feedback adaptation. Typical cycle structures used in practice are 8–12 weeks on followed by 4–8 weeks off, though no controlled human studies have validated any specific cycling schedule.

• Re-initiation considerations: When re-initiating after a break, a conservative approach is to restart at the lower end of the previous dose range and re-check liver and kidney panels at 4–6 weeks rather than assume prior tolerance.

Sourcing and Quality

• Authenticity and species verification: Bulbine natalensis is sometimes confused with related species (e.g., Bulbine frutescens) that have different phytochemical profiles. Reputable suppliers should specify the exact species on the certificate of analysis (CoA), ideally with botanical authentication.

• Standardization: Many supplements are sold as 10:1 or 20:1 stem extracts. Standardization to total saponins, anthraquinones, or specific marker compounds is uncommon; absent standardization, dose-to-dose consistency is uncertain.

• Plant part: Most rodent efficacy data use stem extracts. Products using leaf, root, or whole-plant material may have different phytochemistry and should not be assumed equivalent to stem-extract-based studies.

• Third-party testing: Look for products with third-party testing certificates (e.g., NSF, USP, Informed Choice, or independent ISO 17025 lab CoAs) covering identity, potency, heavy metals (lead, cadmium, arsenic, mercury), microbial contamination, and pesticides; this is especially important for African-sourced botanicals where supply chains are less regulated.

• Reputable suppliers: No major reputable supplement brand has established itself as the dominant source of Bulbine natalensis monoproducts. Smaller specialty botanical manufacturers that publish per-batch certificates of analysis and engage independent third-party labs (e.g., Nutraceuticals International Group, NOW Foods, and Pure Encapsulations as examples of brands with established CoA disclosure practices for their botanical lines) tend to be more reliable than unbranded online sellers; in all cases, preference should be given to suppliers that disclose species verification, plant part, extract ratio, and sourcing region.

• Avoid proprietary blends: Many “test booster” products bury Bulbine natalensis in proprietary blends without disclosing per-ingredient amounts; these formulations make dosing, monitoring, and risk assessment effectively impossible.

Practical Considerations

• Time to effect: Marketed claims and rodent studies suggest changes in androgen-related markers over 1–2 weeks of daily use. Subjective effects (libido, energy) reported by users typically take 2–4 weeks; whether these reflect a true pharmacological signal or expectation effects is unverified.

• Common pitfalls: Frequent missteps include using Bulbine natalensis without a baseline liver and kidney panel; stacking it with other hepatotoxic herbs or alcohol; using indefinite daily dosing without cycling; relying on proprietary-blend products with unknown per-dose content; and confusing it with related Bulbine species.

• Regulatory status: Bulbine natalensis is sold as a dietary supplement in the United States and most Western markets and is not approved as a drug for any indication. It is unregulated for testosterone-related claims, and the U.S. Food and Drug Administration (FDA) does not pre-approve such products for safety or efficacy.

• Cost and accessibility: Cost is generally moderate (typical retail $20–60/month in the United States), and accessibility through online specialty retailers is good. Quality and authenticity vary substantially across brands, so cost is rarely the limiting practical factor.

Interaction with Foundational Habits

• Sleep: Direction of interaction is potentially indirect and bidirectional; no human sleep studies on Bulbine natalensis exist. Mechanistically, sustained sleep restriction is itself a powerful suppressor of endogenous testosterone, so the apparent benefit of any pro-androgenic intervention is markedly limited in chronically sleep-deprived users. Practical consideration: sleep hygiene and adequate duration (7–9 hours) are foundational; inconsistent sleep will likely mute any signal from the intervention and should be addressed first.

• Nutrition: Direction of interaction is indirect and possibly potentiating in well-fed states. Sufficient dietary fat (cholesterol substrate for steroidogenesis), zinc, magnesium, and vitamin D status are required for endogenous testosterone production; in deficiency states the apparent effect of any pro-androgenic intervention is blunted. Practical considerations: take Bulbine natalensis with food to reduce gastrointestinal effects; avoid simultaneous heavy alcohol intake; ensure adequate dietary protein (~1.6 g/kg/day for active individuals) and micronutrient sufficiency.

• Exercise: Direction of interaction is potentially potentiating but not validated. Resistance training itself acutely raises testosterone and improves long-term androgen receptor sensitivity; combining a pro-androgenic botanical with structured resistance training is the typical real-world use case but no controlled trial has tested this combination for Bulbine natalensis. Practical considerations: prioritize the resistance-training stimulus (compound lifts, progressive overload, 3–5 sessions/week); avoid using the supplement as a substitute for training rather than an adjunct.

• Stress management: Direction of interaction is potentially potentiating in chronically stressed individuals via reduction in cortisol-driven HPG-axis suppression. Chronic high cortisol blunts testosterone via central and peripheral pathways; addressing stress (meditation, controlled breathing, sufficient recovery) is likely to do more for testosterone than any modest botanical effect. Practical consideration: pair use with active stress-management practices rather than relying on the supplement to overcome chronic stress-driven suppression.

Monitoring Protocol & Defining Success

Baseline testing before initiating Bulbine natalensis establishes both an androgen reference profile (to determine whether any intervention is warranted) and a hepatic/renal safety reference (to detect on-treatment changes). Ongoing monitoring is then conducted at defined intervals during use.

Ongoing monitoring cadence: at 4–6 weeks of use, again at 12 weeks (typical end of an initial cycle), and then every 3–6 months if cycling is continued long-term. Hormonal panels should ideally be drawn fasted, in the morning (between 7:00 and 10:00 AM), to align with diurnal testosterone peaks.

Biomarker	Optimal Functional Range	Why Measure It?	Context/Notes
Total testosterone	600–900 ng/dL (adult men)	Primary efficacy marker	Conventional reference range typically 264–916 ng/dL; functional medicine targets the upper-normal range. Fasting morning draw, 7:00–10:00 AM.
Free testosterone	9–25 pg/mL (adult men, calculated or direct)	Bioavailable androgen fraction	Often more informative than total when SHBG is altered. Same-draw timing as total testosterone.
SHBG	20–45 nmol/L (adult men)	Modulates free testosterone	Conventional reference 10–57 nmol/L; high SHBG can mask functional androgen deficiency.
LH	2–8 mIU/mL	Distinguishes primary from secondary signals	Helps interpret whether testosterone changes reflect HPG-axis modulation.
FSH	1.5–10 mIU/mL	Pituitary-gonadal signaling	Important if fertility is a consideration.
Estradiol (sensitive)	20–35 pg/mL (adult men)	Aromatization product of testosterone	Elevations may produce gynecomastia or fluid retention; sensitive (LC-MS/MS) assay preferred for men.
ALT	<30 U/L	Hepatic safety	Conventional upper limit often 40–55 U/L; functional range is tighter and detects early hepatotoxic signal.
AST	<30 U/L	Hepatic safety	See ALT; elevated AST/ALT ratio raises suspicion of alcohol-related or muscle-source elevation.
ALP	40–110 U/L	Hepatic and bone safety	Useful adjunct for cholestatic injury patterns.
GGT	<30 U/L	Sensitive marker of hepatic and biliary stress	Often the earliest marker to rise with anthraquinone or alcohol-related hepatic stress.
Total bilirubin	0.3–1.0 mg/dL	Hepatic clearance	Sustained elevation in combination with ALT/AST elevation is a stop signal.
BUN	10–18 mg/dL	Renal safety	Conventional 7–20 mg/dL; functional target slightly tighter.
Creatinine	0.7–1.1 mg/dL (men); use eGFR for interpretation	Renal safety	Adjust for muscle mass; interpret in conjunction with eGFR.
eGFR	>90 mL/min/1.73 m²	Renal filtration capacity	Drops >10–15% from baseline warrant evaluation and likely discontinuation.
Hematocrit	40–48% (men)	Sustained androgen elevation can raise hematocrit	Sustained values >52% warrant evaluation; relevant for any meaningful pro-androgenic effect.
Prostate-specific antigen (PSA)	<2.5 ng/mL (men >40)	Prostate safety with androgen modulation	Baseline value is a reference; rising trends warrant urology evaluation.

Qualitative markers to track during use:

• Subjective libido and sexual function
• Morning erection frequency
• Energy levels through the day
• Mood, motivation, and sense of drive
• Sleep quality and morning grogginess
• Recovery between training sessions
• Strength progression in resistance training
• Body composition trends (waist circumference, lean-mass perception)
• Any signs of hepatic or renal stress (jaundice, dark urine, edema, persistent fatigue, right upper quadrant discomfort)

Emerging Research

• Ongoing or planned clinical trials: As of the creation date, no actively recruiting or completed registered trials specifically evaluating Bulbine natalensis for testosterone in humans were identifiable on clinicaltrials.gov. This itself is a notable gap given the popularity of the ingredient in supplement formulations.

• Phytochemical characterization studies: Continued plant-chemistry research aims to identify which constituents (saponins, anthraquinones, alkaloids, phenolics) drive any pro-androgenic effect, which would support both selective extraction for efficacy and potentially safer formulations that minimize anthraquinone load. This direction could strengthen the case for the intervention if a single active compound with a more favorable safety profile is identified.

• Toxicology dose-response studies: Refined rodent toxicology work mapping the precise dose-response curve for hepatic and renal effects is needed; current data suggest a relatively narrow therapeutic window. This direction could weaken the case for the intervention if the no-observed-adverse-effect level (NOAEL) translates to human-equivalent doses below typical marketed dosing.

• Independent replication of androgenic findings: Most positive androgenic findings — including Yakubu & Afolayan, 2010 on anabolic-androgenic activity and Yakubu & Afolayan, 2009 on sexual behaviour — come from a small number of related research groups. Independent replication in additional rodent models, using standardized extracts and broader endpoints (including HPG-axis dynamics over time), is needed to assess generalizability. Re-examination of the toxicology series (Afolayan & Yakubu, 2009) by independent labs is similarly needed.

• First-in-human pharmacokinetic and safety studies: Basic Phase 1 work (oral pharmacokinetics, single- and multiple-dose safety, hepatic and renal biomarkers) in healthy adults is the most pressing missing piece; without it, the entire human case rests on translation from rodent studies.

• Comparative efficacy with better-studied botanicals: Head-to-head studies versus more rigorously studied androgen-supporting herbs (e.g., ashwagandha (Withania somnifera), fenugreek, Eurycoma longifolia) would help clarify whether Bulbine natalensis provides any advantage justifying its risk profile.

Conclusion

Bulbine natalensis is a southern African botanical traditionally used for wound healing and as a tonic, repurposed in the modern supplement market as a natural testosterone booster. The case for that repositioning rests almost entirely on a small body of rodent studies suggesting central and gonadal stimulation of androgen production, with reports of meaningful testosterone elevations and improved sexual-behavior markers in male rats.

The same body of literature, however, raises hepatic and renal safety concerns at moderate-to-high doses, including elevated liver enzymes, altered kidney function markers, and histological changes. Direct human evidence is limited to a single short, small placebo-controlled safety trial that found no clinically significant changes in hepatic or renal markers at one dose, and the broader human evidence base is sparse. The result is a notable mismatch between the ingredient’s market presence and the strength of the supporting human evidence. The positive androgenic findings come almost entirely from one research group, while the most active proponents are supplement manufacturers with a direct commercial interest in continued use; both are relevant conflicts of interest to weigh.

For an audience focused on optimization through evidence-aware decisions, the testosterone-elevating claims rest on rodent data alone, while rodent toxicology consistently flags hepatic and renal signals. The body of evidence is immature and uncertain, with the strongest claims and strongest cautions both originating from a narrow literature base. The asymmetry between commercial visibility and underlying evidence is itself a defining feature of the current landscape.

Top - Benefits - Risks - Protocol